Ganeden BC30 Approved in Asian Markets

Ganeden Biotech’s GanedenBC30 received approval by food and drug authorities in four significant Asian markets: Japan, India, Taiwan and the Philippines.

CLEVELAND—Ganeden Biotech’s GanedenBC30 (Bacillus coagulans GBI-30, 6086) probiotic ingredient received approval by food and drug authorities in four significant Asian markets: Japan, India, Taiwan and the Philippines.

GanedenBC30 is available as a result of the established partnerships between Maypro Industries in Japan and Connell Bros. Company in India, Taiwan and the Philippines.

"Japan, Taiwan, Philippines and India are significant markets within Asia, where the consumers are already familiar with the benefits of probiotics," said Stephen Quinn, international business development and regulatory manager of Ganeden Biotech. "The regulatory approvals provide a great deal of opportunity for probiotic innovation within these thriving functional food and beverage markets, and we are thrilled to be able to introduce the unique formulating capabilities of GanedenBC30."

On October 15 to 17, Ganeden Biotech will be exhibiting in conjunction with Connell Bros. at Food Ingredients Asia in Jakarta, Indonesia (booth F21). Also, visit the "Food for a Quality Life" conference on October 16 to hear Quinn speak during the "Advances in Nutrition and Health" track about Bacillus coagulans -A spore forming bacteria as novel probiotics in Asia.

Earlier this year, Ganeden Biotech received a new patent, which covers probiotic Bacillus coagulans in all coffee, tea and cereal including GanedenBC30 (U.S. Patent #8,697,055 B2).

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish